一财直击第十一批国家药品集采开标，有哪些新变化？

Core Viewpoint - The article discusses the 11th batch of national organized drug procurement, highlighting its focus on transparency, quality assurance, and competitive pricing mechanisms in the pharmaceutical industry [3][10][13]. Group 1: Procurement Details - The 11th batch of drug procurement includes 55 varieties, covering treatment areas such as anti-infection, anti-tumor, asthma, diabetes, cardiovascular, and neurological drugs [3]. - The procurement process involved a two-round revival mechanism, allowing more companies to qualify, which is expected to extend the bidding time compared to previous batches [10]. - Since 2018, the national level has conducted 10 batches of drug procurement, covering 435 drugs and nearly 800 companies, involving over 2,000 representative products [10]. Group 2: Principles and Optimizations - The procurement adheres to principles of stabilizing clinical use, ensuring quality, preventing excessive competition, and avoiding collusion [10][11]. - The reporting method for medical institutions has been optimized, allowing them to report either by generic name or specific brand, with 77% of the 46,000 institutions reporting by brand [10]. - Quality standards have been raised, requiring that production lines have no GMP violations in the past two years [10]. Group 3: Transparency and Competition - A significant highlight of this procurement is its emphasis on transparency, with the procurement office publicly explaining the selection rules and conducting online sessions for medical institutions [13]. - On average, 14 companies have applied for each variety, indicating that most companies are expected to qualify, although competition may be fierce for some varieties with a high number of bidders [13][15]. - The National Medical Insurance Administration issued a warning in August for companies to conduct cost-benefit analyses and maintain rational pricing in light of high competition [15].